AU2021417405A1 - Oral solid cannabinoid oil composition for treating central nervous system disorders - Google Patents

Oral solid cannabinoid oil composition for treating central nervous system disorders Download PDF

Info

Publication number
AU2021417405A1
AU2021417405A1 AU2021417405A AU2021417405A AU2021417405A1 AU 2021417405 A1 AU2021417405 A1 AU 2021417405A1 AU 2021417405 A AU2021417405 A AU 2021417405A AU 2021417405 A AU2021417405 A AU 2021417405A AU 2021417405 A1 AU2021417405 A1 AU 2021417405A1
Authority
AU
Australia
Prior art keywords
cannabinoid oil
cannabinoid
oil
microcrystalline cellulose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021417405A
Other languages
English (en)
Other versions
AU2021417405A9 (en
Inventor
Syed M Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2021417405A1 publication Critical patent/AU2021417405A1/en
Publication of AU2021417405A9 publication Critical patent/AU2021417405A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2021417405A 2021-01-08 2021-12-23 Oral solid cannabinoid oil composition for treating central nervous system disorders Pending AU2021417405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135198P 2021-01-08 2021-01-08
US63/135,198 2021-01-08
PCT/EP2021/087505 WO2022148672A1 (en) 2021-01-08 2021-12-23 Oral solid cannabinoid oil composition for treating central nervous system disorders

Publications (2)

Publication Number Publication Date
AU2021417405A1 true AU2021417405A1 (en) 2023-06-22
AU2021417405A9 AU2021417405A9 (en) 2025-01-09

Family

ID=79731086

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021417405A Pending AU2021417405A1 (en) 2021-01-08 2021-12-23 Oral solid cannabinoid oil composition for treating central nervous system disorders

Country Status (7)

Country Link
US (1) US20240050377A1 (https=)
EP (1) EP4274554A1 (https=)
JP (1) JP2024502309A (https=)
CN (1) CN116546983A (https=)
AU (1) AU2021417405A1 (https=)
CA (1) CA3200382A1 (https=)
WO (1) WO2022148672A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8808736B2 (en) * 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CA2909591C (en) * 2013-04-23 2017-03-28 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
WO2019159174A1 (en) * 2018-02-16 2019-08-22 Icdpharma Ltd. Colonic delivery of cannabinoids in solid solution compositions
WO2020016656A2 (en) * 2018-07-18 2020-01-23 Glatt Gmbh Extended release formulations of cannabinoids
CA3140813A1 (en) * 2019-06-13 2021-12-07 Imbucanna, Inc Compressible cannabinoid pharmaceutical composition
EP4087547A1 (en) * 2020-01-08 2022-11-16 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders

Also Published As

Publication number Publication date
CN116546983A (zh) 2023-08-04
WO2022148672A1 (en) 2022-07-14
JP2024502309A (ja) 2024-01-18
EP4274554A1 (en) 2023-11-15
CA3200382A1 (en) 2022-07-14
US20240050377A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
JP6105761B2 (ja) 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
RU2590979C2 (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
RU2744576C2 (ru) Пероральные фармацевтические композиции месалазина
US9707260B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US12186281B2 (en) Oral solid cannabinoid oil composition for treating gastrointestinal disorders
US11207276B2 (en) Multiparticulate L-menthol formulations and related methods
US20240050377A1 (en) Oral solid cannabinoid oil composition for treating central nervous system disorders
WO2017125856A1 (en) Formulations in modified-release tablets containing high-dosage mesalazine, process for their preparation and their use
AU2015203894A1 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Legal Events

Date Code Title Description
SREP Specification republished